Like type-2 diabetes mellitus (T2DM), neurodegenerative disorders and stroke are an ever increasing, health, social and economic burden for developed Westernized countries. Age is an important risk factor in all of these; due to the rapidly increasing rise in the elderly population T2DM and neurodegenerative disorders, both represent a looming threat to healthcare systems. Whereas several efficacious drugs are currently available to ameliorate T2DM, effective treatments to counteract pathogenic processes of neurodegenerative disorders are lacking and represent a major scientific and pharmaceutical challenge. Epidemiological data indicate an association between T2DM and most major neurodegenerative disorders, including Alzheimer's and Parkinson's diseases. Likewise, there is an association between T2DM and stroke incidence. Studies have revealed that common pathophysiological features, including oxidative stress, insulin resistance, abnormal protein processing and cognitive decline, occur across these. Based on the presence of shared mechanisms and signalling pathways in these seemingly distinct diseases, one could hypothesize that an effective treatment for one disorder could prove beneficial in the others. Glucagon-like peptide-1 (GLP-1)-based anti-diabetic drugs have drawn particular attention as an effective new strategy to not only regulate blood glucose but also to reduce apoptotic cell death of pancreatic beta cells in T2DM. Evidence supports a neurotrophic and neuroprotective role of GLP-1 receptor (R) stimulation in an increasing array of cellular and animal neurodegeneration models as well as in neurogenesis. Herein, we review the physiological role of GLP-1 in the nervous system, focused towards the potential benefit of GLP-1R stimulation as an immediately translatable treatment strategy for acute and chronic neurological disorders. AbbreviationsAb, amyloid-b; AD, Alzheimer's disease; APP, amyloid-b precursor protein; ALS, amyotrophic lateral sclerosis; BDNF, brain-derived neurotrophic factor; BrdU, bromodeoxyuridine; CNTF, ciliary neurotrophic factor; DCX, doublecortin; DOPAC, 3,4-dihydroxyphenylacetic acid; DPP-IV, dipedylpeptidase-IV; ERG, electroretinogram; Ex-4, exendin-4; GIP, gastric inhibitor peptide; GLP-1, glucagon-like peptide-1; GLP-1R, glucagon-like peptide-1 receptor; HVA; homovanillic acid; HD, Huntington's disease; LTP, long term potentiation; MCAo, middle cerebral artery occlusion; MPTP, 1-methyl-4-phenyl-1,2,3,4,6-tetrahydroxypyridine; MPP + , 1-methyl-4-phenylpyridinum ion; NGF, nerve growth factor; 6-OHDA, 6-hydroxydopamine; PD, Parkinson's disease; RA, retinoic acid; VMAT2, vesicle monoamine transporter 2 BJP British Journal of Pharmacology DOI:10.1111DOI:10. /j.1476DOI:10. -5381.2012 1586 British Journal of Pharmacology (2012) 166 1586-1599Published 2012. This article is a U.S. Government work and is in the public domain in the USA. IntroductionNeurodegenerative and cerebrovascular disorders are an ever increasing, health, social and economic burden for developed Westernized count...

Eight novel 2-(2, 6-dioxopiperidin-3-yl)phthalimidine EM-12 dithiocarbamates 9 and 10, N-substituted 3-(phthalimidin-2-yl)-2, 6-dioxopiperidines 11–14 and 3-substituted 2, 6-dioxopiperidines 16 and 18 were synthesized as tumor necrosis factor-α (TNF-β) synthesis inhibitors. Synthesis involved utilization of a novel condensation approach, a one-pot reaction involving addition, iminium rearrangement and elimination, to generate the phthalimidine ring required for the creation of compounds 9–14. Agents were, thereafter, quantitatively assessed for their ability to suppress the synthesis on TNF-β in a lipopolysaccharide (LPS)-challenged mouse macrophage-like cellular screen, utilizing cultured RAW 264.7 cells. Whereas compounds 9, 14 and 16 exhibited potent TNF-α lowering activity, reducing TNF-α by up to 48% at 30 μM, compounds 12, 17 and 18 presented moderate TNF-α inhibitory action. The TNF-α lowering properties of these analogues proved more potent than that of revlimid (3) and thalidomide (1). In particular, N-dithiophthalimidomethyl-3-(phthalimidin-2-yl)-2, 6-dioxopiperidine 14 not only possessed the greatest potency of the analogues to reduce TNF-α synthesis, but achieved this with minor cellular toxicity at 30 μM. The pharmacological focus of the presented compounds is towards the development of well-tolerated agents to ameliorate the neuroinflammation that is commonly associated with neurodegenerative disorders, epitomized by Alzheimer’s disease and Parkinson’s disease.